A SCHOOL-BASED PROGRAM TO PREVENT INHALANT USE IN ALASKA

描述(由申请人提供)：一项为期三年的针对美国印第安人的循证药物滥用预防计划的研究被提议用于在阿拉斯加原住民(尤皮克人、廷吉特人和因努皮特人)、高加索人和其他人口比例不同的社区中打击吸入剂和其他药物的使用。这项研究的目的是(A)使循证药物预防计划适应于在阿拉斯加农村小学实施，(B)进行试点测试，以评估其实施质量，可能与实施质量相关的因素，计划效果，以及可能解释所指出的任何计划效果的因素。这项研究的主要结果是认知和行为技能中介，据信这些中介中介了该计划对青少年前吸入剂使用的潜在影响。为了实现这些结果，将调整以证据为基础的学校毒品预防培训计划，以提高阿拉斯加农村社区青少年前儿童抵制吸入剂使用的认知和行为技能。阿拉斯加农村16个社区的学校系统已经同意参与这项研究，其中8对社区将被随机分配到实验和控制条件下。这16个社区大多数只有一所小学，将代表位于该州不同地区的中学和高等教育服务中心以及支线阿拉斯加原住民村庄的混合体，人口规模从433人到8835人不等。这项研究将把注意力集中在减少毒品问题上，这一问题在高危和服务不足的人群中几乎没有受到关注。

DESCRIPTION (provided by applicant): A three-year study of an adapted evidence-based substance abuse prevention program for American Indians is proposed to combat inhalant use and other drug use among youth in communities with varying proportions of Alaska Natives (Yupik, Tingit, and Inupiat), Caucasians, and other populations. The study aims are to (a) adapt an evidence-based drug prevention program to be implemented in rural Alaska elementary schools and (b) conduct a pilot test to assess its implementation quality, factors that may be associated with implementation quality, program effects, and factors that might explain any program effects noted. The primary outcomes of this study are cognitive and behavioral skills mediators that are believed to mediate the program's potential effects on inhalant use among pre-adolescents. To achieve these outcomes, an evidence-based school drug prevention training program will be adapted to increase cognitive and behavioral skills to resist the use of inhalants among pre-adolescents in rural Alaskan communities. Agreements have been obtained from school systems in 16 communities in rural Alaska to participate in the study in which eight pairs of communities will be randomly assigned to experimental and control conditions. The 16 communities, most of which only have only one elementary school, will represent a mixture of secondary and tertiary service centers and feeder Alaska Native villages that are located in various regions of the state, with population size ranging from 433 to 8,835. This study will focus attention on reducing a drug problem that has received little attention among a high risk and underserved population.